The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

Protein–protein interactions (PPIs) are involved at all levels of cellular organization, thus
making the development of PPI inhibitors extremely valuable. The identification of selective …

Stapled α− helical peptides have emerged as a promising new modality for a wide range of
therapeutic targets. Here, we report a potent and selective dual inhibitor of MDM2 and …

The tumor suppressor p53 is often inactivated via its interaction with endogenous inhibitors
mouse double minute 4 homolog (MDM4 or MDMX) or mouse double minute 2 homolog …

The tumor suppressor protein p53 induces or represses the expression of a variety of target
genes involved in cell cycle control, senescence, and apoptosis in response to oncogenic or …

Tumor suppressor p53 is an attractive cancer therapeutic target because it can be
functionally activated to eradicate tumors. Direct gene alterations in p53 or interaction …

The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor
suppressor protein p53—a cellular process initiated by MDM2 and/or MDMX binding to the …

Mdm2 is a major negative regulator of the tumor suppressor p53 protein, a protein that plays
a crucial role in maintaining genome integrity. Inactivation of p53 is the most prevalent defect …

Activation of p53 tumor suppressor by antagonizing its negative regulator murine double
minute (MDM) 2 has been considered an attractive strategy for cancer therapy and several …

Anti-tumorigenic mechanisms mediated by the tumor suppressor p53, upon oncogenic
stresses, are our bodies' greatest weapons to battle against cancer onset and development …